Daniel Savic

Daniel Savic

Auto-generated profile, based on publicly available information

Daniel Savic

Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Molecular Cell
Verified
Journal Article
Closed access
JGJason Gertz
Jason Gertz
DSDaniel Savic
Daniel Savic
KVKatherine E. Varley
Katherine E. Varley
EPE. Christopher Partridge
E. Christopher Partridge
ASAlexias Safi
Alexias Safi
RMRichard M. Myers
Richard M. Myers

9 September 2015 in Genome Research
Verified
Journal Article
Open access
PDF file
DSDaniel Savic
Daniel Savic
EPE. Christopher Partridge
E. Christopher Partridge
KNKimberly M. Newberry
Kimberly M. Newberry
SSSophia B. Smith
Sophia B. Smith
SMSarah K. Meadows
Sarah K. Meadows
RMRichard M. Myers
Richard M. Myers
Chromatin immunoprecipitation followed by next-generation DNA sequencing (ChIP-seq) is a widely used technique for identifying transcription factor (TF) binding events throughout an entire genome. However, ChIP-seq is limited by the availability of suitable ChIP-seq grade antibodies, and the vast majority of commercially available antibodies fail to generate usable data sets. To ameliorate these technical obstacles, we present a robust methodological approach for performing ChIP-seq through epitope tagging of endogenous TFs. We used clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based genome editing technology to develop CRISPR epitope tagging ChIP-seq (CETCh-seq) of DNA-binding proteins. We assessed the feasibility of CETCh-seq by tagging several DNA-binding proteins spanning a wide range of endogenous expression levels in the hepatocellular carcinoma cell line HepG2. Our data exhibit strong correlations between both replicate types as well as with standard ChIP-seq approaches that use TF antibodies. Notably, we also observed minimal changes to the cellular transcriptome and to the expression of the tagged TF. To examine the robustness of our technique, we further performed CETCh-seq in the breast adenocarcinoma cell line MCF7 as well as mouse embryonic stem cells and observed similarly high correlations. Collectively, these data highlight the applicability of CETCh-seq to accurately define the genome-wide binding profiles of DNA-binding proteins, allowing for a straightforward methodology to potentially assay the complete repertoire of TFs, including the large fraction for which ChIP-quality antibodies are not available.

4 May 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SPSteven W Paugh
Steven W Paugh
EBErik J Bonten
Erik J Bonten
DSDaniel Savic
Daniel Savic
Laura B. RamseyLaura B. Ramsey
Laura B. Ramsey
WTWilliam E Thierfelder
William E Thierfelder
WEWilliam E Evans
William E Evans
William Evans and colleagues find that the proinflammatory genes CASP1 and NLRP3 are expressed at higher levels in primary acute lymphoblastic leukemia cells that are resistant than in those that are sensitive to glucocorticoid treatment. They find that CASP1 mediates glucocorticoid resistance through cleavage of the glucocorticoid receptor. Glucocorticoids are universally used in the treatment of acute lymphoblastic leukemia (ALL), and resistance to glucocorticoids in leukemia cells confers poor prognosis. To elucidate mechanisms of glucocorticoid resistance, we determined the prednisolone sensitivity of primary leukemia cells from 444 patients newly diagnosed with ALL and found significantly higher expression of CASP1 (encoding caspase 1) and its activator NLRP3 in glucocorticoid-resistant leukemia cells, resulting from significantly lower somatic methylation of the CASP1 and NLRP3 promoters. Overexpression of CASP1 resulted in cleavage of the glucocorticoid receptor, diminished the glucocorticoid-induced transcriptional response and increased glucocorticoid resistance. Knockdown or inhibition of CASP1 significantly increased glucocorticoid receptor levels and mitigated glucocorticoid resistance in CASP1-overexpressing ALL. Our findings establish a new mechanism by which the NLRP3-CASP1 inflammasome modulates cellular levels of the glucocorticoid receptor and diminishes cell sensitivity to glucocorticoids. The broad impact on the glucocorticoid transcriptional response suggests that this mechanism could also modify glucocorticoid effects in other diseases.

14 June 2011 in Genome Research
Verified
Journal Article
Open access
PDF file
DSDaniel Savic
Daniel Savic
HYHonggang Ye
Honggang Ye
IAIvy Aneas
Ivy Aneas
SPSoo-Young Park
Soo-Young Park
GBGraeme I. Bell
Graeme I. Bell
MNMarcelo A. Nobrega
Marcelo A. Nobrega
Genome-wide association studies (GWAS) have consistently implicated noncoding variation within the TCF7L2 locus with type 2 diabetes (T2D) risk. While this locus represents the strongest genetic determinant for T2D risk in humans, it remains unclear how these noncoding variants affect disease etiology. To test the hypothesis that the T2D-associated interval harbors cis-regulatory elements controlling TCF7L2 expression, we conducted in vivo transgenic reporter assays to characterize the TCF7L2 regulatory landscape. We found that the 92-kb genomic interval associated with T2D harbors long-range enhancers regulating various aspects of the spatial–temporal expression patterns of TCF7L2, including expression in tissues involved in the control of glucose homeostasis. By selectively deleting this interval, we establish a critical role for these enhancers in robust TCF7L2 expression. To further determine whether variation in Tcf7l2 expression may lead to diabetes, we developed a Tcf7l2 copy-number allelic series in mice. We show that a null Tcf7l2 allele leads, in a dose-dependent manner, to lower glycemic profiles. Tcf7l2 null mice also display enhanced glucose tolerance coupled to significantly lowered insulin levels, suggesting that these mice are protected against T2D. Confirming these observations, transgenic mice harboring multiple Tcf7l2 copies and overexpressing this gene display reciprocal phenotypes, including glucose intolerance. These results directly demonstrate that Tcf7l2 plays a role in regulating glucose tolerance, suggesting that overexpression of this gene is associated with increased risk of T2D. These data highlight the role of enhancer elements as mediators of T2D risk in humans, strengthening the evidence that variation in cis-regulatory elements may be a paradigm for genetic predispositions to common disease.

23 January 2012 in Genome Biology
Verified
Journal Article
Open access
PDF file
NSNoboru Jo Sakabe
Noboru Jo Sakabe
DSDaniel Savic
Daniel Savic
MNMarcelo A Nobrega
Marcelo A Nobrega
Distal transcription enhancers are cis-regulatory elements that promote gene expression, enabling spatiotemporal control of genetic programs such as those required in metazoan developmental processes. Because of their importance, their disruption can lead to disease.

1 August 2017 in Immunity
Verified
Journal Article
Closed access
DCDanielle A. Chisolm
Danielle A. Chisolm
DSDaniel Savic
Daniel Savic
AMAmanda J. Moore
Amanda J. Moore
ABAndre Ballesteros-Tato
Andre Ballesteros-Tato
BLBeatriz León
Beatriz León
AWAmy S. Weinmann
Amy S. Weinmann